Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study

Date
2012
Author
MacManus, David G.
Limmroth, Volker
Polman, Chris H.
Schmierer, Klaus
Yousry, Tarek A.
Meluzinova, Eva
Dufek, Michal
Yang, Minhua
Dawson, Kate
O'Neill, Gilmore N.
Eraksoy, Mefkure
Kappos, Ludwig
Gold, Ralf
Miller, David H.
Havrdova, Eva
Metadata
Show full item record
Abstract
Background: In a phase 2b study in patients with relapsing-remitting MS (RRMS), BG-12 240 mg three times daily significantly reduced the number of new gadolinium-enhanced (Gd+) lesions from weeks 12 to 24 (primary end point) by 69% compared with placebo.
URI
http://hdl.handle.net/20.500.12627/89506
https://doi.org/10.1177/1352458511421054
Collections